La prevenzione cardiovascolare negli anni Venti del XXI secolo – Lezioni apprese e direzioni future
Diego Vanuzzo;Simona Giampaoli
DOI: https://doi.org/10.36158/97888929535987
Note
1
Rose G., Rose’s Strategy of Preventive Medicine, with commentary by Kay-Tee Khaw and Michael Marmot, Ox- ford University Press, Oxford 2008, p. 38.
2
Dagan N., Barda N., Kepten E. (et al.), BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting, N Engl J Med, 2021;1412-1423
3
Salomoni M.G., Di Valerio Z., Gabrielli E. (et al.), Hesitant or Not Hesitant? A Systematic Review on Global Covid-19 Vaccine Acceptance in Different Populations, Vaccines (Basel) 2021 Aug; 9(8): 873. Published online 2021 Aug 6. DOI: 10.3390/vaccines9080873
4
The Lancet, Latest global disease estimates reveal perfect storm of rising chronic diseases and public health failures fuel- ling Covid-19 pandemic [available at http://www.healthdata. org/news-release/lancet-latest-global-disease-estimates-re- veal-perfect-storm-rising-chronic-diseases-and; latest access 24/10/21]
5
GBD 2019 Diseases and Injuries Collaborators, Global burden of 369 diseases and injuries in 204 countries and territo- ries, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019, Lancet 2020; 396: 1204-22 [see also http:// www.healthdata.org/results/gbd_summaries/2019/cardiovas- cular-diseases-level-2-cause; latest access 20/11/21]
6
GBD 2019 Risk Factors Collaborators, Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019, Lancet 2020; 396: 1223-49 [see also http://www.healthdata. org/results/gbd_summaries/2019; latest access 20/11/21]
7
Last J.M. (ed. by), A Dictionary of Epidemiology, 4th edition, Oxford University Press, New York 2001
8
Kannel W.B., Dawber T.R., Kagan A., Revotskie N., Stokes J. 3rd, Factors of risk in the development of coronary heart disease—six-year follow-up experience, The Framingham Study, Ann Int Med 1961;55:33-50
9
Braunwald E., The rise of cardiovascular medicine, Eur Heart J, 2012;33:838-845
10
Keys A., Aravanis C., Blackburn H. (et al.), Seven Countries. A Multivariate Analysis of Death and Coronary Heart Disease, A Commonwealth Fund Book, England, Harvard University Press, Cambridge, Massachussets and London 1980
11
Intersalt Cooperative Research Group, Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion, BMJ 1988;297:319-328
12
Kannel W.B., An overview of the risk factors for cardi- ovascular disease, in Kaplan N.M., Stamler J., Prevention of Coronary Heart Disease, WB Saunders Company, Philadel- phia 1983.
13
Rose G., Sick individuals and sick populations, Inter- national Journal of Epidemiology, 1985;14:32-38
14
Strasser T., Reflections on cardiovascular diseases, In- terdiscip Science Rev, 1978;3:225–230
15
Stamler J., Neaton J.D., Garside D.B., Daviglus M.L., Current status: six extablished major risk factors – and low risk, in Marmot M., Elliott P. (ed. by), Coronary Heart Disease Epidemiology: From Aetiology to Public Health, Oxford University Press, Oxford 2005, p. 46-54
16
Pearce N., Epidemiology in a changing world: varia- tion, causation and ubiquitous risk factors, Int J Epidemiol, 2011;40:503–512
17
SCORE2 working group and ESC Cardiovascular risk collaboration, SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Eu- rope, Eur Heart J 2021, 42:2439-2454.
18
Id., SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geo- graphical risk regions. Eur Heart J 2021; 42: 2455-2467
19
Goff D.C. Jr, Lloyd-Jones D.M., Bennett G. (et al.), 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, JACC, 2014, 63: 2935–2959
20
Ferrario M., Chiodini P., Chambless L.E., Cesana G., Vanuzzo D., Panico S., Sega R., Pilotto L., Palmieri L., Giampaoli S., Prediction of coronary events in a low incidence population: assessing accuracy of the CUORE Cohort Study pre- diction equation, Int J Epidemiol, 2005;34:413-421
21
Giampaoli S., Palmieri L., Donfrancesco C., Panico S., Vanuzzo D., Pilotto L., Ferrario M., Cesana G., Mat- tiello A., On behalf of The CUORE Project Research Group. Cardiovascular risk assessment in Italy: the CUORE Project risk score and risk chart, Ital J P Health, 2007; 4:102-109
22
Palmieri L., Donfrancesco C., Giampaoli S., Trojani M., Panico S., Vanuzzo D., Pilotto L., Cesana G., Ferrario M., Chiodini P., Sega R., Stamler J., Favorable cardiovascu- lar risk profile and 10-year coronary heart disease incidence in women and men: results from the Progetto CUORE, Eur J Car- diovasc Prev Rehabil, 2006;13:562-570.
23
Giampaoli S., Palmieri L., Panico S., Vanuzzo D., Fer- rario M., Chiodini P., Pilotto L., Donfrancesco C., Cesana G., Sega R., Stamler J., Favorable cardiovascular risk profile (low risk) and 10-year stroke incidence in women and men: findings from 12 Italian population samples, Am J Epidemiol, 2006;163:893-902.
24
Sidebottom A.C., Miedema M.D., Benson G. (et al.), The impact of a population-based prevention program on cardiovascular events: Findings from the heart of new Ulm pro- ject, Am H J, 2021, 239:38-51
25
Fernández-Alvira J.M., Fernández-Jiménez R., De Miguel M. (et al.), The challenge of sustainability: Long-term results from the Fifty-Fifty peer group-based intervention in car- diovascular risk factors, Am H J, 2021, 240:81-88
26
Kuulasmaa K., Tunstall-Pedoe H., Dobson A., Fortmann S., Sans S., Tolonen H., Evans A., Ferrario M., Tuomilehto J., Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations, Lancet, 2000;355:675-687
27
Tunstall-Pedoe H., Vanuzzo D., Hobbs M., Ma- honen M., Cepaitis Z., Kuulasmaa K. (et al.), Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortali- ty across the WHO MONICA Project populations, Lancet, 2000;355(9205):688-700
28
Tunstall-Pedoe H., Kuulasmaa K., Mahonen M., Tolonen H., Ruokokoski E., Amouyel P., Contribution of trends in survival and coronary-event rates to changes in cor- onary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determi- nants in cardiovascular disease, Lancet, 1999;353(9164):1547- 1557
29
Karlinsky A., Kobak D., Tracking excess mortali- ty across countries during the Covid-19 pandemic with the World Mortality Dataset, eLife, 2021;10:e69336 DOI: 10.7554/ eLife.69336
30
Hessamia A., Shamshiriande A., Heydaria K. (et al.), Cardiovascular diseases burden in Covid-19: Systematic review and meta-analysis, Am J Emergency Medicine, 2021, 382-391
31
Marenberg M.E., Risch N., Berkman L.F., Floderus B., de Faire U., Genetic susceptibility to death from coro- nary heart disease in a study of twins, N Engl J Med, 1994, 330:1041-1046
32
Lloyd-Jones D.M., Nam B.H., D’Agostino R.B. Sr (et al.), Parental cardiovascular disease as a risk factor for cardi- ovascular disease in middle-aged adults: a prospective study of parents and offspring, JAMA, 2004, 291:2204-2211.
33
Khera A.M., Emdin C.A., D. Phil., Drake I. (et al.), Genetic risk, adherence to a healthy lifestyle, and coronary dis- ease, N Engl J Med, 2016;375:2349-2358
34
Khera A.V., Chaffin M., Aragam K.G. (et al.), Ge- nome-wide polygenic scores for common diseases identify indi- viduals with risk equivalent to monogenic mutations, Nature genetics, 2018, 50:1219-1224
35
Bolli A., Di Domenico P., Pastorino R., Busby G.B., Bottà G., Risk of coronary artery disease conferred by low-den- sity lipoprotein cholesterol depends on polygenic background, Circulation, 2021, 143: 1452-1454.
36
K.G., Dobbyn A., Judy R. (et al.), Limita- tions of contemporary guidelines for managing patients at high genetic risk of coronary artery disease, JACC, 2020, 75:2769- 2780.
37
Damask A., Steg P.G., Schwartz G.G. (et al.), Pa- tients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from aliro- cumab treatment in the ODYSSEY OUTCOMES trial. 2020, Circulation, 141:624-636
38
Natarajan P., Young R., Stitziel N.O. (et al.), Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting, Circulation, 2017; 135: 2091-2101
39
Frary C.E., Blicher M.K., Olesen T.B. (et al.), Cir- culating biomarkers for long-term cardiovascular risk stratifi- cation in apparently healthy individuals from the MONICA 10 cohort, Eur J Prev Cardiol, 2020;27:570-578
40
Kozakova M., Palombo C., Imaging subclinical ather- osclerosis in cardiovascular risk stratification, Eur J Prev Car- diol, 2021;28:247-249
41
Faggiano P., Dasseni N., Gaibazzi N. (et al.), Cardiac calcification as a marker of subclinical atherosclerosis and pre- dictor of cardiovascular events: A review of the evidence, Eur J Prev Cardiol, 2019;26:1191-1204
42
Antonopoulos A.S., Angelopoulos A., Tsioufis K., Antoniades C., Tousoulis D., Cardiovascular risk stratifica- tion by coronary computed tomography angiography imaging: current state-of-the-art, Eur J Prev Cardiol, 2021;, zwab067, https://doi.org/10.1093/eurjpc/zwab067
43
Tamarappoo B.K., Lin Ab., Commandeur F. (et al.), Machine learning integration of circulating and imaging biomarkers for explainable patient-specific prediction of cardiac events: a prospective study, Atherosclerosis, 2021, 318: 76-82
44
Quer G., Arnaout R., Henne M., Arnaout R., Machine learning and the future of cardiovascular care, JACC State-of-the-Art Review, JACC 2021, 77: 300-313
45
Palmnäs M., Brunius C,. Shi L. (et al.), Perspective: metabotyping – a potential personalized nutrition strategy for precision prevention of cardiometabolic disease, Advances in Nutrition 2020, 11:524-532
46
Traversi D., Pulliero A., Izzotti A. (et al.), Precision medicine and public health: new challenges for effective and sustainable health, J. Pers. Med, 2021, 11:135, https://doi. org/10.3390/jpm11020135
47
O’Connor E.A., Evans C.V., Rushkin M.C. (et al.), Behavioral counseling to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors Updated Evidence Report and Systematic Review for the US Preventive Services Task Force, JAMA. 2020;324:2076-2094
48
US Preventive Services Task Force, Behavio- ral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors US Preventive Services Task Force Recommendation Statement, JAMA, 2020;324(20):2069-2075
49
Jorgensen T., Capewell S., Prescott E., Allender S., Sans S., Zdrojewski T., De Bacquer D., de Sutter J., Franco O.H., Logstrup S., Volpe M., Malyutina S., Marques-Vidal P., Reiner Z., Tell G.S., Verschuren W.M., Vanuzzo D., PEP section of EACPR. Population-level chang- es to promote cardiovascular health. Eur J Prev Cardiol, 2013;20:409-421
50
Visseren F.L.J., Mach F., Smulders Y.M. (et al.), 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice, Eur Heart J, 2021; 42:3227-3337
51
Journath G., Niklas Hammar N., Vikström M. (et al.), A Swedish primary healthcare prevention programme focusing on promotion of physical activity and a healthy lifestyle reduced cardi- ovascular events and mortality: 22-year follow-up of 5761 study par- ticipants and a reference group, Br J Sports Med, 2020;54:1294-1299
52
D’Ascenzi F., Sciaccaluga C., Cameli M. (et al.), When should cardiovascular prevention begin? The importance of antenatal, perinatal and primordial prevention, Eur J Prev Cardiol, 2021; 28:361-369
53
Sekikawa A., Horiuchi B.Y., Edmundowicz D. (et al.), A “natural experiment” in cardiovascular epidemiology in the early 21st century, Heart 2003;89:255-257
54
Zatonski W.A., McMichael A.J., Powles J.W., Eco- logical study of reasons for sharp decline in mortality from ischaemic heart disease in Poland since 1991, BMJ, 1998; 316:1047-1051